CO6620016A2 - Métodos de tratamiento de transtorno ópticos - Google Patents
Métodos de tratamiento de transtorno ópticosInfo
- Publication number
- CO6620016A2 CO6620016A2 CO12235608A CO12235608A CO6620016A2 CO 6620016 A2 CO6620016 A2 CO 6620016A2 CO 12235608 A CO12235608 A CO 12235608A CO 12235608 A CO12235608 A CO 12235608A CO 6620016 A2 CO6620016 A2 CO 6620016A2
- Authority
- CO
- Colombia
- Prior art keywords
- method further
- methods
- reducing
- further involves
- methylfolate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención se refiere a métodos para tratar trastornos ópticos o para reducir o aliviar los signos, síntomas o afecciones patológicas relacionados con dichos trastornos ópticos. En particular, se proporcionan métodos para tratar trastornos ópticos o reducir los síntomas de los mismos, implicando los métodos la administración de uno o más compuestos de folato corriente abajo y/o metil-B12. En una realización particular, el método comprende la administración de L-metilfolato. En otras realizaciones, el método implica administrar tanto L-metilfolato como metil-B12. En otras realizaciones adicionales, el método implica además reducir la ingesta alimentaria de ácido fólico. En ciertas realizaciones, el método implica además identificar un organismo objetivo con un mal funcionamiento en uno o más de los ciclos de folato o B4. En ciertas realizaciones, dicho mal funcionamiento es una o más de las mutaciones C677T y A1298C. En otras realizaciones adicionales, el método implica además identificar un organismo objetivo que tiene deficiencia de vitaminas B-12 y D3 pero que posee exceso de homocisteína.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35852210P | 2010-06-25 | 2010-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6620016A2 true CO6620016A2 (es) | 2013-02-15 |
Family
ID=45353101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12235608A CO6620016A2 (es) | 2010-06-25 | 2012-12-28 | Métodos de tratamiento de transtorno ópticos |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8822431B2 (es) |
| BR (1) | BR112012032716A2 (es) |
| CA (1) | CA2836445C (es) |
| CL (1) | CL2012003636A1 (es) |
| CO (1) | CO6620016A2 (es) |
| MX (1) | MX348297B (es) |
| WO (1) | WO2011163301A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348297B (es) * | 2010-06-25 | 2017-06-06 | Global Healthcare Focus Llc | Métodos de tratamiento de trastornos ópticos. |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| MX2014000197A (es) * | 2011-06-21 | 2014-06-11 | Global Healthcare Focus Llc | Metodos para prevenir o tratar estados patologicos relacionados con ciertas anormalidades metabolicas. |
| PT3389407T (pt) | 2015-12-14 | 2024-01-19 | Nestle Sa | Composição nutricional e fórmula para lactentes para promover mielinização de novo |
| EP3616700A1 (en) * | 2018-08-29 | 2020-03-04 | Aprofol AG | Folate preparations for use in the treatment of eye diseases |
| EP3875094A1 (en) * | 2020-03-02 | 2021-09-08 | Aprofol AG | Folate preparations for the treatment of ocular diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19910682B4 (de) | 1999-03-10 | 2004-09-02 | Dierkes, Jutta, Dr. | Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6583152B2 (en) | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
| US20040116351A1 (en) | 2002-12-06 | 2004-06-17 | Fast Balance, Inc. | Method for enhancing the natural reward system for exercise |
| US7429569B2 (en) | 2004-01-29 | 2008-09-30 | Fast Balance, Inc. | Compositions and methods for the regulation of homocysteine levels within the body |
| US20080206360A1 (en) | 2004-12-01 | 2008-08-28 | Curt Hendrix | Folate based migraine treatment |
| BRPI0608293A2 (pt) | 2005-03-10 | 2012-05-02 | Sciele Pharma Inc | preparações nutricionais |
| US20060281822A1 (en) | 2005-04-20 | 2006-12-14 | Cardinal Associates, Inc. | Treatment and prevention of elevated homocysteine |
| GB0917745D0 (en) | 2009-10-09 | 2009-11-25 | Mathilde Valayer | Compositions for the prevention or treatment of migraine |
| MX348297B (es) * | 2010-06-25 | 2017-06-06 | Global Healthcare Focus Llc | Métodos de tratamiento de trastornos ópticos. |
-
2011
- 2011-06-22 MX MX2012015249A patent/MX348297B/es active IP Right Grant
- 2011-06-22 BR BR112012032716A patent/BR112012032716A2/pt not_active Application Discontinuation
- 2011-06-22 US US13/166,207 patent/US8822431B2/en active Active
- 2011-06-22 CA CA2836445A patent/CA2836445C/en active Active
- 2011-06-22 WO PCT/US2011/041351 patent/WO2011163301A1/en active Application Filing
-
2012
- 2012-12-21 CL CL2012003636A patent/CL2012003636A1/es unknown
- 2012-12-28 CO CO12235608A patent/CO6620016A2/es not_active Application Discontinuation
-
2014
- 2014-08-14 US US14/459,771 patent/US9770464B2/en active Active
-
2017
- 2017-09-25 US US15/714,802 patent/US10278987B2/en active Active
-
2019
- 2019-05-07 US US16/405,503 patent/US11351189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200000836A1 (en) | 2020-01-02 |
| CA2836445A1 (en) | 2011-12-29 |
| BR112012032716A2 (pt) | 2018-07-10 |
| US20150038452A1 (en) | 2015-02-05 |
| US10278987B2 (en) | 2019-05-07 |
| WO2011163301A1 (en) | 2011-12-29 |
| US20180028556A1 (en) | 2018-02-01 |
| CA2836445C (en) | 2019-06-11 |
| US11351189B2 (en) | 2022-06-07 |
| MX2012015249A (es) | 2014-03-27 |
| MX348297B (es) | 2017-06-06 |
| US8822431B2 (en) | 2014-09-02 |
| CL2012003636A1 (es) | 2014-02-14 |
| US20110319356A1 (en) | 2011-12-29 |
| US9770464B2 (en) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6620016A2 (es) | Métodos de tratamiento de transtorno ópticos | |
| AR088165A1 (es) | Proteinas de funcion dual para tratar trastornos metabolicos | |
| NZ716627A (en) | Methods of treating behavioral symptoms of neurological and mental disorders | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| BR112015023910A2 (pt) | terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer | |
| GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
| EA201491339A1 (ru) | Замещенные аннеллированные пиримидины и триазины и их применение | |
| BR112016010166A2 (pt) | métodos para usar interleucina-10 para tratar doenças e distúrbios | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| EA201400119A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| BR112016006188A2 (pt) | método de tratamento com um protocolo de fármaco e um sistema com uma base de dados relacional acoplado a um ou mais dispositivos eletrônicos ; sistema para a gestão de um tratamento medicamentoso pela administração de um fármaco a um paciente e método de gestão de um tratamento com drogas usando um sistema de informação com uma base de dados relacional. | |
| DOP2015000070A (es) | Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| BR112014007357A2 (pt) | métodos de monitoramento terapêutico de fármacos de varredura de nitrogênio | |
| EA201591679A1 (ru) | Способ нетоксического лечения абстиненции, вызванной лекарственным средством | |
| EA033067B1 (ru) | Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения | |
| BR112015003729A2 (pt) | composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente | |
| AR087918A1 (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf | |
| BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
| NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
| CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina | |
| CO6450623A2 (es) | Parasiticidas sanguineos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |